QS-21

DCTPepD ID  DCTPepD0100

Active Ingredients   QS-21

Description  A purified, natural saponin isolated from the soapbark tree Quillaja saponaria Molina with potential immunoadjuvant activity. When co-administered with vaccine peptides, QS21 may increase total antitumoral vaccine-specific antibody responses and cytotoxic T-cell responses.

Synonyms  NIAID VEU 016; Stimulon; QA 21V1; QS-21-Api

Disease  Melanoma, Genital herpes, HIV, Hepatitis (viral, B), Influenza

Classification

  

Immunoadjuvant

Structure Information


Molecular Formula  Not available

Molecular Weight  Not available

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  Not available

InChI  Not available

InChI_Key Not available

SMILES  Not available

External Codes


PubChem CID  Not available

DrugBank Accession Number  DB05400

NCI Thesaurus Code  C1478  

UNII  61H83WZX3U   GSRS

CAS  141256-04-4



Drug approval


Drug indication
    Investigated for use/treatment in genital herpes, HIV infection, hepatitis (viral, B), influenza, malaria, melanoma, and viral infection.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00470574 Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21 Breast Cancer Not Applicable Treatment
NCT00036933 Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates Plus The Immunological Adjuvant QS21 Prostate Cancer Phase 1 Treatment
NCT00004249 Immunization Using Polysialic Acid-KLH or N-Propionylated Polysialic Acid-KLH Conjugate Plus the Immunological Adjuvant QS-21 in Patients With Small Cell Lung Cancer Who Have Achieved a Major Response to Initial Therapy Lung Cancer Phase 2 Treatment
NCT00004156 Vaccination of High Risk Breast Cancer Patients With MUC-1 (Glycosylated) Keyhole Limpet Hemocyanin Conjugates Plus the Immunological Adjuvant QS21 Breast Cancer Phase 1 Treatment
NCT05638698 Phase II Randomized Trial Combining Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA) Pancreas Cancer Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.